A 47-year-old woman received combination therapy with prednisolone (PSL), danazol, cepharanthin, ascorbic acid, and cimetidine for the treatment of idiopathic thrombocytopenic purpura. The platelet count was well controlled for over 1 year. Then the PSL tablet formulation was altered from Tablet A to Tablet B with the same treatment regimen, but the platelet counts fell drastically thereafter. However, the platelet counts recovered by changing the PSL tablet formulation back from Tablet B to Tablet A. In vitro dissolution testing was undertaken to assess bioequivalence between Tablet A and Tablet B. PSL in Tablet B was released more slowly compared with that in Tablet A regardless of the medium pH conditions, and the diŠerence in the release rate between the two tablet formulations increased with increasing medium pH value. The diŠerence exceeded the allowance limit (15％) for judgement of bioequivalence under conditions above pH 4, indicating that Tablet A and Tablet B might be nonbioequivalent. The intragastric pH of the patient was probably raised due to coadministration of cimetidine. Therefore the present results suggest that the disparity in the immunosuppressive eŠects between the two PSL tablet formulations was attributable to the diŠerence in their dissolution behavior in the gastrointestinal tract. We consider that it is better to avoid interchanging PSL tablet formulations in clinical practice.
INTRODUCTION
Prednisolone (PSL), a synthetic glucocorticosteroid, is commonly used to treat a variety of immunologic, allergic, and in‰ammatory diseases. In Japan, as in other countries, a number of pharmaceutical companies market their original PSL formulations based on extensive clinical demand and the management strategy for stable proˆt, although the end price of the pharmaceutical products is regulated by the health insurance system. The Ministry of Health, Labor and Welfare requires that each PSL formulation be manufactured to meet the quality assurance requirements speciˆed in the Japanese Pharmacopoeia (JP), 1) but it has not been conˆrmed whether the e‹cacy and safety are equivalent among the PSL formulations. In recent clinical reports on treatment with levothyroxine, 2) valproic acid, 3) clozapine, 4, 5) and warfarin, 6) it was pointed out that there was signiˆcant disparity in the therapeutic outcome between tablet formulations, although the quantity of active ingredients and dosage form were identical. This is attributed to the lack of bioequivalence between the tablet formulations because vehicles and manufacturing processes may diŠer.
In this paper, we present a case of ‰uctuating immunosuppressive control in a patient after interchanging two brand-name PSL tablet formulations and examine the release characteristics of PSL from the two PSL tablet formulations by in vitro dissolution testing to discuss this clinical event. The dissolution test was carried out at 37±0.5°C in accordance with the speciˆcations in the Japanese Pharmacopoeia, 14th edition (JP XIV), using roundbottomed glass chambers attached to a rotation paddle apparatus (Model PTW-II, Pharm Test). The test media used in this study were JP XIV reference ‰uid (distilled water), JP XIVˆrst ‰uid (pH 1.2), 0.05 M acetate buŠer (pH 4.0), 0.1 M phosphate buŠer (pH 6.0), and JP XIV second ‰uid (pH 6.8). The medium volume was 900 ml, and stirring speed was set at 50 rpm. The amount of PSL released into the test medium from the tablets was determined by successive monitoring of absorbance at 248 nm by using a ‰ow-through cell system (Model UV-1200 spectrophotometer, Shimadzu) after passing the solution through â ne glassˆlter (F-72, Toyama Sangyo). Aqueous solution of PSL (5.56 mg/ml [5 mg/900 ml]) was used as a standard. Measurements were repeated 18 times under the same conditions, and the release rate was deˆned as the mean of their determinations. The validity of the adopted spectrophotometric method for the dissolution test was conˆrmed by HPLC analysis. 7) 
MATERIALS AND METHODS

Standard
RESULTS
Case Presentation
The patient was a 47-yearold woman (weight 53 kg, height 157 cm), who did not smoke and drink alcohol, who had been diagnosed with idiopathic thrombocytopenic purpura (ITP) and systemic lupus erythematosus (SLE) 18 years previously. She received pulse therapy with steroid and cyclophosphamide, g-globulin injection, and platelet transfusion when ITP worsened. After remission she was being treated with only oral drugs during outpatient follow-up at the Hospital of Shiga University of Medical Science. The platelet count was maintained at the level above 20×10 3 /mm 3 during concomitant treatment with PSL (25 mg/day, Tablet A [5 mg/T]), danazol (100 mg/day), cepharanthin (60 mg/day), ascorbic acid (1.5 g/day), and cimetidine (800 mg/day) for over 1 year. PSL was administered once daily in the morning. The daily PSL dose was tentatively reduced to an average 22.5 mg/ day (alternate administrations of 25 mg/day and 20 mg/day), but a signiˆcant decrease in platelet count was observed thereafter. The dosage was returned to 25 mg/day, and the platelet counts recovered.
On February 20, 2001, the patient visited another hospital for outpatient consultation with a referral from our hospital, due to her stable disease. The same treatment regimen was continued, although another PSL tablet (Tablet B [5 mg/T]) was prescribed instead of Tablet A. On March 27, 2001, the patient consulted our hospital because of severe general fatigue with increased purpura and gum bleeding. As the platelet counts at that time were found to have drastically fallen to 3×10 3 /mm 3 , she was hospitalized immediately. Compliance with the prescribed treatment regimen was unfailing according to the patient. No signs of recurrence of SLE were indicated by clinical laboratory tests. On admission, Tablet A was prescribed in place of Tablet B, although the treatment regimen was unchanged. Following the change from Tablet B to Tablet A, the platelet count increased to the original level after about 1 week, and the bleeding improved markedly. She was discharged on April 8 because the serious symptoms had resolved, and the platelet count was well controlled thereafter. Figure 1 shows the changes in platelet count in the patient from January 2000.
Dissolution Test
The dissolution proˆle of PSL from Tablet A and Tablet B is shown in Fig. 2 . Both tablets were apparently disintegrated and dissolved within 50 min, and at least 85％ of labeled PSL was released within 15 min from Tablet A. However, PSL of Tablet B was released more slowly than that in Tablet A, irrespective of the medium conditions. Figure 3 shows the diŠerence in the release rate of PSL between Tablet A and Tablet B when 85％ of the PSL in Tablet A had been released. The diŠerence increased with the increase in pH value of the medium, and the disparity exceeded 15％ under medium conditions above pH 4.
DISCUSSION
ITP is an immunoregulatory disorder characterized by platelet destruction associated with an overproduction of speciˆc autoantibody that augments platelet phagocytosis in the reticuloendothelial system. PSL is recommended as theˆrst-choice immunosuppressant for maintenance of platelet function in patients with chronic ITP. In the present case, a remarkable worsening of ITP (continuous bleeding due to platelet count reduction) occurred after changing from Tablet A to Tablet B, and then a pronounced improvement of the ITP symptoms with recovery of platelet count was observed only after changing from Tablet B back to Tablet A, although all other medica- tions remained unchanged. The application of Naranjo's algorithm 8) indicated a probable association between ‰uctuation in the therapeutic response and interchange of PSL formulations, although rechallenge with Tablet B was not attempted. In previous reports, therapeutic failure after prescribing another formulation of prednisone, a prodrug of PSL, was demonstrated, and it was conˆrmed that such cases were attributed to diŠerences in dissolution proˆles among the prednisone tablet formulations. [9] [10] [11] As shown by the dissolution test in the present study, the release rate of PSL in Tablet B was lower The release rate of PSL from Tablet B was calculated at the time when 85％ of the PSL was released in Tablet A. Each column shows subtraction of the release rate of Tablet B from the release rate (85％) of Tablet A under the various medium conditions. Dotted line represents allowance limit (15 ％) for judgment of bioequivalence.
than that in Tablet A (Fig. 2) . This result was compatible with the clinical observations described above. As previous in vitro/in vivo correlation studies employing healthy subjects indicated that the rank orders of the dissolution rate of immediate-release PSL tablets were similar to those of the gastrointestinal absorption rate, 12, 13) PSL in Tablet B was likely to be absorbed more slowly as compared with that in Tablet A. Based on the authorized guidance of the dissolution test, 14) it can be interpreted that there is a high possibility of nonbioequivalence between the two products if not less than a 15％ diŠerence in the release rate is observed at the time when approximately 85％ is released from one product. PSL was released from the tablets in a pH-dependent manner, and the extent of diŠerence in the release rate of Tablet A and Tablet B was outside the allowance limit (15％) for the judgment of bioequivalence 14) under the medium conditions above pH 4 (Fig. 3) . This suggests that Tablet A and Tablet B might be nonbioequivalent. The present patient was coadministered the H 2 -receptor antagonist cimetidine at a daily dose of 800 mg for prevention of peptic ulcer caused by PSL, and it was suspected that the intragastric pH value was elevated above pH 5 due to depression of acid secretory function. 15, 16) Therefore this physiological status might aŠect the absolute bioavailability of PSL in Tablet B in connection with the further delay in the absorption rate.
The international criteria for the decision on in vivo bioequivalence between the test and reference products is that the 90％ conˆdence interval for the ratios of the geometric mean AUC and Cmax values falls within 80-125％. 17) According to this acceptance criteria, a 20％ diŠerence in AUC and Cmax between two products is acceptable even if they are judged to be bioequivalent. Our patient once experienced a decrease in platelet counts after a 10％ dose reduction in PSL from 25 mg/day to 22.5 mg/ day. That episode suggests that she is highly susceptible to modiˆcation of PSL dosage even though the dose adjustment is within the acceptable range of bioequivalence, and it provides strong support for the signiˆcant diŠerence in the therapeutic response to the two PSL formulations.
The Japanese guidelines require the dissolution test to assess the bioequivalence of generic drugs to innovator drugs in addition to in vivo comparison in pharmacokinetic studies. 18) However, there is no distinction between generic and innovator products in the PSL formulations sold on the market in Japan, because PSL is a JP-listed drug that can be manufactured without restriction under patent permission. The dissolution test of PSL is thus not formally required, but the present study provided evidence that there is a signiˆcant disparity in dissolution behavior among PSL formulations, and that this diŠerence was likely to re‰ect ‰uctuations in the clinical eŠect.
In conclusion, we consider that it is better to avoid interchanging PSL tablet formulations in clinical practice regardless of brand, taking its strong biological action into account.
